Acute Urticaria in Adults

Overview

Acute urticaria is a common dermatological condition characterized by the sudden onset of transient, pruritic, erythematous wheals (hives) that result from mast cell degranulation and localized histamine release in the dermis. The condition is defined by symptom duration of less than six weeks, distinguishing it from chronic urticaria which persists beyond this timeframe. Individual wheals are characteristically evanescent, typically resolving within 24 hours without residual skin changes, though new lesions may continue to appear throughout the acute episode. [1,2]

The clinical importance of acute urticaria lies in its high prevalence, affecting approximately 15-25% of the general population at some point in their lifetime, and its potential association with life-threatening anaphylaxis. [3] While most cases are self-limiting and respond well to antihistamine therapy, the emergency physician must systematically exclude systemic involvement, particularly respiratory compromise and cardiovascular instability, which would indicate progression to anaphylaxis requiring immediate epinephrine administration. The condition may occur in isolation or be accompanied by angioedema, a related phenomenon involving deeper dermal and submucosal tissues.

From a pathophysiological perspective, acute urticaria represents a spectrum of mast cell-mediated reactions ranging from localized IgE-dependent allergic responses to direct non-immunological mast cell activation. Understanding the mechanistic differences between histamine-mediated urticaria and bradykinin-mediated angioedema (particularly ACE inhibitor-induced) is clinically critical, as the latter does not respond to conventional antihistamine or corticosteroid therapy and carries significant risk of airway compromise. [4] Current evidence-based management emphasizes prompt recognition, appropriate pharmacological intervention with non-sedating H1-antihistamines as first-line therapy, and judicious use of short-course corticosteroids for severe presentations. [1,5]

---

Epidemiology

Prevalence and Incidence

Acute urticaria represents one of the most common dermatological presentations in both primary care and emergency department settings. Population-based studies demonstrate a lifetime prevalence of 15-25%, with annual incidence rates estimated at 1-3% of the general population. [3,6] The condition exhibits no significant sex predilection, though some studies suggest a slight female predominance (female-to-male ratio approximately 1.2-1.5:1). [7]

The distinction between acute and chronic urticaria has important epidemiological and prognostic implications. Acute urticaria (duration less than 6 weeks) is significantly more common than chronic urticaria, accounting for approximately 60-70% of all urticaria cases presenting to medical attention. [9] Progression from acute to chronic urticaria occurs in approximately 10-20% of cases, with higher rates observed in adults compared to children. [10]

Demographics and Risk Factors

While acute urticaria can affect individuals of any age, peak incidence occurs in young to middle-aged adults (20-40 years). [7] Certain populations demonstrate increased susceptibility:

Atopic individuals: Patients with personal or family history of atopic conditions (asthma, allergic rhinitis, atopic dermatitis) demonstrate 2-3 fold increased risk of developing acute urticaria. [11]

Infection-related urticaria: Viral upper respiratory tract infections represent the most common identifiable trigger in acute urticaria, particularly in children and young adults, accounting for 30-50% of cases where an etiology can be determined. [12]

Medication exposure: NSAIDs and antibiotics (particularly beta-lactams) are the most frequently implicated medications, with NSAIDs causing urticaria through both IgE-mediated mechanisms and direct mast cell activation. [13]

Geographic and Temporal Variation

Geographic variation in acute urticaria incidence reflects regional differences in allergen exposure, infectious disease prevalence, and medication prescribing patterns. Seasonal peaks have been documented, with increased incidence during spring and summer months correlating with increased insect sting exposure and food allergen consumption. [14] In temperate climates, viral infection-triggered urticaria demonstrates winter predominance paralleling respiratory virus circulation patterns.

---

Aetiology and Pathophysiology

Classification of Urticaria

Urticaria is classified according to multiple taxonomic systems based on duration, mechanism, and trigger factors:

By Duration

By Mechanism

Common Aetiological Triggers

A specific causative trigger can be identified in approximately 40-60% of acute urticaria cases, with the remainder classified as idiopathic. [1,15]

Infections (30-50% of Identifiable Cases)

Viral infections: Upper respiratory tract infections (rhinovirus, coronavirus, adenovirus), infectious mononucleosis (EBV), hepatitis viruses, and norovirus gastroenteritis. Viral-induced urticaria typically occurs during the acute infection phase and resolves with viral clearance. [12]

Bacterial infections: Streptococcal pharyngitis, urinary tract infections, Helicobacter pylori gastritis (more commonly associated with chronic urticaria), and dental infections. [12]

Parasitic infections: More prevalent in endemic regions; includes helminthic infections and parasitic gastroenteritis.

Medications (20-30% of Identifiable Cases)

NSAIDs represent a unique category, capable of causing urticaria through multiple mechanisms: (1) IgE-mediated allergy to specific NSAID compounds, (2) cross-reactive inhibition of cyclooxygenase-1 (COX-1) affecting arachidonic acid metabolism, and (3) direct non-immunological mast cell degranulation. [13]

Foods (10-20% of Identifiable Cases)

Common food allergens follow the "Big 8" pattern in Western populations: milk, eggs, peanuts, tree nuts, fish, shellfish, wheat, and soy. [16] Food-induced acute urticaria typically manifests within minutes to 2 hours of ingestion and follows an IgE-mediated mechanism. Food additives (tartrazine, benzoates, sulfites) have historically been implicated but recent evidence suggests their role is significantly overstated, with true prevalence less than 1%. [17]

Insect Stings and Bites (5-10% of Cases)

Hymenoptera venom (bees, wasps, hornets, fire ants) causes IgE-mediated urticaria as part of local reactions or systemic anaphylaxis. Mosquito and other arthropod bites may cause localized papular urticaria through both immediate and delayed hypersensitivity mechanisms.

Physical Urticarias (Subset of Chronic Inducible Urticaria)

While more commonly associated with chronic urticaria, physical stimuli can trigger acute episodes:

• Dermographism (symptomatic dermographism): Whealing following stroking or scratching of skin
• Cold urticaria: Exposure to cold air, water, or objects
• Cholinergic urticaria: Triggered by increase in core body temperature (exercise, hot showers, emotional stress)
• Solar urticaria: UV or visible light exposure
• Delayed pressure urticaria: Pressure applied to skin (belts, straps, prolonged sitting/standing)
• Aquagenic urticaria: Contact with water (rare)
• Vibratory angioedema: Vibratory stimuli (rare, often hereditary)

Cellular and Molecular Pathophysiology

Exam Detail: #### Mast Cell Biology and Activation

Mast cells are tissue-resident immune cells derived from CD34+ hematopoietic progenitors, strategically located in skin, respiratory mucosa, and gastrointestinal tract. The skin contains approximately 7,000-20,000 mast cells per mm³, primarily distributed in the upper and mid-dermis around blood vessels and nerves. [18]

Mast cell activation occurs through multiple pathways:

IgE-dependent activation (Classical allergic pathway):

1. Prior allergen exposure leads to sensitization with production of allergen-specific IgE antibodies
2. IgE binds to high-affinity FcεRI receptors on mast cell surface (each mast cell expresses 100,000-300,000 FcεRI receptors)
3. Re-exposure to allergen causes cross-linking of adjacent IgE-FcεRI complexes
4. Cross-linking triggers intracellular signaling cascade involving tyrosine kinases (Lyn, Syk), phospholipase C, and calcium mobilization
5. Calcium influx triggers immediate degranulation (minutes) and delayed lipid mediator synthesis (hours)

IgE-independent activation:

• Direct mast cell activators: Opioids, radiocontrast media, compound 48/80, and certain peptides (substance P, vasoactive intestinal peptide) activate mast cells through G-protein coupled receptors or direct membrane effects, bypassing IgE [18]
• Complement anaphylatoxins: C3a and C5a bind to mast cell receptors (C3aR, C5aR) triggering degranulation
• Physical stimuli: Mechanical forces, temperature changes, and pressure trigger mast cell activation through mechanosensitive ion channels and temperature-sensitive receptors (TRPV channels)
• Neuropeptides: Substance P released from cutaneous nerve endings can directly activate mast cells via MRGPRX2 receptors (Mas-related G-protein coupled receptor X2)

Mediator Release and Vascular Effects

Activated mast cells release three categories of mediators:

Preformed granule mediators (released within seconds-minutes):

• Histamine: The primary mediator causing vasodilation and increased vascular permeability. Histamine binds to H1 receptors on endothelial cells causing gap junction formation and plasma extravasation into dermis, creating the characteristic wheal. H1 receptor activation also stimulates sensory nerve endings producing pruritus. [2]
• Tryptase: Serine protease that activates protease-activated receptor-2 (PAR-2) on endothelial cells, contributing to vascular permeability. Elevated serum tryptase (measured 30 minutes to 3 hours after symptom onset) serves as a marker of mast cell degranulation
• Heparin: Anticoagulant proteoglycan
• Tumor necrosis factor-α (TNF-α): Pre-stored in granules, rapidly released

Newly synthesized lipid mediators (generated within minutes-hours):

• Prostaglandin D2 (PGD2): Produced via cyclooxygenase-2 (COX-2) pathway from arachidonic acid. Causes vasodilation and contributes to late-phase inflammatory responses
• Leukotrienes C4, D4, E4 (LTC4/D4/E4): Generated via 5-lipoxygenase pathway. LTC4/D4/E4 (collectively termed "slow-reacting substance of anaphylaxis") cause prolonged smooth muscle contraction and vascular permeability, contributing to sustained whealing and angioedema [19]
• Platelet-activating factor (PAF): Potent inflammatory mediator causing platelet aggregation, neutrophil activation, and vasodilation

Cytokines and chemokines (produced hours after activation):

• IL-4, IL-5, IL-13: Promote eosinophil recruitment and IgE production
• IL-6, IL-8: Neutrophil chemoattractants
• TNF-α: Endothelial activation and upregulation of adhesion molecules

Vascular Response and Wheal Formation

The characteristic urticarial wheal develops through the following sequence:

1. Arteriolar vasodilation: Histamine H1 receptor activation on vascular smooth muscle → increased local blood flow → erythema (red flare)
2. Increased vascular permeability: Endothelial H1 receptor activation → actin-myosin contraction → widening of intercellular gaps → plasma extravasation into dermis
3. Wheal formation: Dermal edema from plasma extravasation creates raised, compressible lesion
4. Axon reflex flare: Histamine stimulates sensory C-fibers → antidromic nerve impulse transmission → neuropeptide release (substance P, CGRP) → neurogenic inflammation and surrounding erythema extending beyond central wheal
5. Pruritus: Histamine and tryptase activate pruriceptive nerve fibers (TRPV1+ neurons) → itch sensation

Individual wheals typically resolve within 2-24 hours as histamine is metabolized by histamine N-methyltransferase and diamine oxidase, and extravasated fluid is reabsorbed via lymphatic drainage.

Angioedema: Deeper Tissue Involvement

Angioedema represents a related but distinct process involving deeper dermal, submucosal, and subcutaneous tissues. While urticaria affects the superficial dermis (papillary and upper reticular dermis), angioedema involves the deep reticular dermis and subcutaneous tissue.

Histamine-mediated angioedema: Occurs concurrently with urticaria in 40-50% of acute urticaria cases, sharing the same mast cell-mediated pathophysiology. Preferentially affects areas with loose connective tissue: lips, periorbital region, genitals, hands, and feet. [2]

Bradykinin-mediated angioedema: Mechanistically distinct from histamine-mediated processes; does NOT respond to antihistamines or corticosteroids. Results from excessive bradykinin production or impaired degradation:

• ACE inhibitor-induced angioedema: ACE (angiotensin-converting enzyme) normally degrades bradykinin. ACE inhibition → bradykinin accumulation → increased vascular permeability in deep tissues. Occurs in 0.1-0.7% of ACE inhibitor users, with higher incidence in Black patients (relative risk 3-4.5 fold). [4,20] Onset can occur within days or after years of ACE inhibitor use (median onset ~1-3 months, but range extends to > 5 years)

• Hereditary angioedema (HAE): Genetic deficiency or dysfunction of C1 esterase inhibitor (C1-INH) → uncontrolled activation of contact system → kallikrein-mediated conversion of high-molecular-weight kininogen (HMWK) to bradykinin. Three types: HAE type I (85%, low C1-INH levels), HAE type II (15%, normal/elevated dysfunctional C1-INH), HAE with normal C1-INH (factor XII mutations). Characterized by recurrent episodes of angioedema WITHOUT urticaria, often triggered by trauma or stress. [21]

Chronic Spontaneous Urticaria: Autoimmune Mechanisms

While chronic spontaneous urticaria (CSU) is beyond the scope of acute urticaria, understanding its pathophysiology provides mechanistic insight. CSU affects approximately 0.5-1% of the population and is characterized by wheals occurring spontaneously for > 6 weeks. [10]

Autoimmune mechanisms account for 30-50% of CSU cases:

Type I autoimmune urticaria: IgG autoantibodies directed against high-affinity IgE receptor (FcεRI) or against IgE itself. These autoantibodies cross-link FcεRI receptors on mast cells and basophils, triggering degranulation independent of allergen exposure. [22]

Type II autoimmune urticaria: IgG or IgM antibodies against specific autoantigens (thyroid peroxidase, tissue transglutaminase, double-stranded DNA), associated with underlying autoimmune conditions (Hashimoto's thyroiditis, celiac disease, systemic lupus erythematosus).

The autologous serum skin test (ASST) can identify functional autoantibodies: patient's serum is injected intradermally; positive test (wheal ≥1.5 mm larger than saline control) suggests presence of histamine-releasing autoantibodies.

---

Clinical Presentation

Cardinal Features of Acute Urticaria

The diagnosis of acute urticaria is primarily clinical, based on characteristic morphological features and temporal evolution of skin lesions:

Morphology of Individual Wheals

Temporal Characteristics (Diagnostically Critical)

Duration of individual wheals: Each individual wheal persists for less than 24 hours (typically minutes to hours) before resolving completely without residual changes. This is the single most important diagnostic criterion. [1,2]

• Wheals lasting > 24 hours suggest alternative diagnoses, particularly urticarial vasculitis
• New wheals may continue to appear while others resolve, giving impression of persistent rash, but each individual lesion should fade within 24 hours

Evanescent nature: Wheals characteristically migrate, with lesions appearing in one location while simultaneously fading in another. Patients may describe lesions "moving around."

Complete resolution: No residual skin changes (no pigmentation, scaling, scarring, or purpura). Presence of residual changes suggests vasculitis or other inflammatory dermatoses.

Symptoms

Pruritus: Intense itching is the predominant symptom, present in > 90% of cases. Pruritus results from histamine and tryptase stimulation of pruriceptive C-fibers. Severity varies from mild to severe, often described as "unbearable" and interfering with sleep and daily activities. [2]

Burning or stinging sensation: Reported by 20-30% of patients, particularly in areas with larger wheals or when angioedema is present.

Pain: Uncommon in uncomplicated urticaria; presence of pain suggests urticarial vasculitis or extensive angioedema.

Associated Angioedema

Angioedema occurs concurrently with urticaria in 40-50% of acute urticaria cases. [2] Key distinguishing features:

Common angioedema sites (in decreasing order of frequency):

1. Lips (upper and lower)
2. Periorbital region (eyelids)
3. Tongue
4. Buccal mucosa
5. Pharynx and larynx (potentially life-threatening)
6. Genitals
7. Hands and feet

History Taking: Critical Questions

A systematic history is essential for trigger identification and anaphylaxis risk stratification:

Temporal Profile

• Onset: When did symptoms begin? (hours, days, weeks)
• Evolution: Are lesions static, worsening, or improving?
• Individual lesion duration: How long does each individual spot last? (Critical: > 24h suggests vasculitis)
• Recurrence pattern: First episode or recurrent? Previous episodes resolved within 6 weeks or chronic pattern?

Trigger Identification

• Medication exposure: Any new medications in past 2-4 weeks? (Particularly NSAIDs, antibiotics, ACE inhibitors)
• Food consumption: New foods, restaurant meals, known food allergens? Timing relative to symptom onset?
• Insect exposure: Recent stings or bites?
• Infection symptoms: Fever, sore throat, cough, urinary symptoms, gastrointestinal upset?
• Physical triggers: Exercise, cold exposure, hot showers, pressure from tight clothing, sunlight?
• Occupational/environmental exposures: Latex, chemicals, new cosmetics, detergents?

Systemic Symptoms (Anaphylaxis Screen)

• Respiratory: Shortness of breath, wheezing, stridor, throat tightness, voice changes, difficulty swallowing?
• Cardiovascular: Dizziness, lightheadedness, syncope, chest pain, palpitations?
• Gastrointestinal: Nausea, vomiting, abdominal cramping, diarrhea? (In context of urticaria suggests anaphylaxis)
• Neurological: Confusion, sense of impending doom?

Past Medical and Family History

• Atopic history: Asthma, allergic rhinitis, atopic dermatitis, food allergies?
• Previous allergic reactions: Anaphylaxis, drug allergies, documented IgE-mediated allergies?
• Chronic urticaria: Previous episodes lasting > 6 weeks?
• Autoimmune conditions: Thyroid disease, rheumatoid arthritis, SLE?
• Family history: Hereditary angioedema, chronic urticaria, atopy?

Physical Examination

Dermatological Examination

Skin assessment:

• Distribution: Localized vs. generalized (trunk, extremities, face)
• Wheal characteristics: Size, shape, color, coalescence
• Dermographism testing: Stroke uninvolved skin firmly with tongue depressor; positive test produces linear wheal within 2-10 minutes, indicating mast cell hyperreactivity
• Residual changes: Assess for petechiae, purpura, pigmentation, or scaling (absence confirms urticaria; presence suggests vasculitis)

Angioedema assessment:

• Lips, tongue, periorbital swelling (measure degree of swelling)
• Oropharyngeal examination (uvula, soft palate, posterior pharynx)
• Hand and foot swelling

Systematic Assessment for Anaphylaxis

Respiratory system:

• Respiratory rate, oxygen saturation
• Auscultation for wheeze, stridor
• Voice quality (muffled or hoarse voice suggests laryngeal edema)
• Ability to swallow secretions

Cardiovascular system:

• Heart rate (tachycardia common in anaphylaxis)
• Blood pressure (hypotension indicates systemic involvement)
• Capillary refill time
• Peripheral perfusion

Gastrointestinal system:

• Abdominal tenderness or cramping
• Nausea/vomiting

Neurological system:

• Mental status (confusion suggests cerebral hypoperfusion in anaphylaxis)

Red Flags Requiring Immediate Intervention

---

Differential Diagnosis

The differential diagnosis of pruritic, erythematous skin lesions is broad. Key distinguishing features differentiate urticaria from mimics:

Urticarial Vasculitis

Key distinguishing features:

• Individual lesions persist > 24 hours (often 24-72 hours)
• Lesions may be painful rather than pruritic
• Residual changes: Petechiae, purpura, or post-inflammatory hyperpigmentation
• Systemic features may be present: Arthralgia, fever, elevated ESR/CRP
• Histology: Leukocytoclastic vasculitis on skin biopsy [23]

Urticarial vasculitis represents a clinically and histologically distinct entity where immune complex deposition causes small vessel inflammation. Associated with systemic conditions (SLE, Sjögren's syndrome, hepatitis C, hypocomplementemic urticarial vasculitis syndrome).

Erythema Multiforme

Key distinguishing features:

• Target or iris lesions (central dusky area, middle pale zone, peripheral erythema)
• Fixed lesions (do not migrate; persist for > 7 days)
• Predilection for acral distribution (hands, feet, elbows, knees)
• Mucous membrane involvement common (particularly oral mucosa)
• Associated triggers: HSV infection (most common), Mycoplasma pneumoniae, medications

Contact Dermatitis (Allergic or Irritant)

Key distinguishing features:

• Distribution corresponds to contactant exposure (e.g., linear pattern from plant allergen, geometric pattern from cosmetics)
• Vesicles and weeping in acute phase
• Pruritus prominent but lesions do not resolve within 24 hours
• Progresses to scaling and lichenification in chronic phase
• Patch testing can identify specific allergens

Drug Eruptions (Morbilliform Drug Reaction)

Key distinguishing features:

• Morbilliform (measles-like) erythematous macules and papules, not raised wheals
• Begins on trunk and spreads to extremities over days
• Does not resolve in less than 24 hours
• May have associated fever, eosinophilia
• Typically begins 7-14 days after drug initiation

Mastocytosis (Cutaneous or Systemic)

Key distinguishing features:

• Persistent brown macules or plaques (urticaria pigmentosa)
• Darier's sign: Whealing and erythema after stroking lesions
• Dermographism often prominent
• Chronic/recurrent rather than acute presentation
• May have systemic symptoms (flushing, hypotension, GI symptoms)
• Elevated baseline serum tryptase (> 20 ng/mL suggests systemic mastocytosis)

Bullous Pemphigoid (Early Urticarial Phase)

Key distinguishing features:

• Elderly patients (typically > 70 years)
• Pruritic urticarial plaques precede blister formation by weeks to months
• Tense bullae eventually develop on urticarial base
• Direct immunofluorescence: Linear IgG and C3 deposition at basement membrane zone

Scabies

Key distinguishing features:

• Intense nocturnal pruritus
• Linear burrows (pathognomonic; found in web spaces, wrists, genitals)
• Papules, vesicles, and excoriations rather than transient wheals
• Contact history; affects close contacts

Arthropod Bites (Papular Urticaria)

Key distinguishing features:

• Grouped papules or wheals, often with central punctum
• Distribution on exposed skin areas
• Lesions persist > 24 hours, develop into papules
• Seasonal pattern or environmental exposure history
• May have delayed hypersensitivity (persistent papules)

Anaphylaxis vs. Uncomplicated Urticaria

Critical distinction (determines need for epinephrine):

Anaphylaxis diagnostic criteria (presence of any ONE criterion within minutes to hours):

1. Acute skin/mucosal involvement (wheals, angioedema, flushing, pruritus) AND at least one of:

   • Respiratory compromise (dyspnea, wheeze, stridor, hypoxemia)
   • Reduced blood pressure or end-organ dysfunction (syncope, incontinence)

2. Two or more of the following after exposure to likely allergen:

   • Skin/mucosal involvement
   • Respiratory compromise
   • Reduced blood pressure
   • Gastrointestinal symptoms (cramping, vomiting)

3. Reduced blood pressure after exposure to known allergen:

   • Adults: SBP less than 90 mmHg or > 30% decrease from baseline [24]

---

Diagnostic Approach

Clinical Diagnosis

Acute urticaria is fundamentally a clinical diagnosis based on history and physical examination findings. Laboratory investigations and imaging are rarely necessary for straightforward cases and should not delay treatment. [1,5]

Diagnostic criteria:

1. Transient, pruritic, erythematous wheals
2. Individual lesions resolving within less than 24 hours without residual changes
3. Duration of overall episode less than 6 weeks (defines "acute")

When Laboratory Testing is Indicated

For most patients presenting with isolated acute urticaria without systemic symptoms, no laboratory testing is required. Testing should be reserved for specific clinical scenarios:

Indications for Laboratory Investigations

Specific Test Interpretations

Serum tryptase: Produced by activated mast cells. Peak levels occur 30 minutes to 3 hours after anaphylaxis onset, returning to baseline by 12-24 hours. [24]

• Interpretation: Acute elevation > 11.4 ng/mL or [1.2 × baseline] + 2 ng/mL suggests mast cell activation
• Limitations: Normal tryptase does not exclude anaphylaxis (sensitivity ~60-80% for systemic anaphylaxis); isolated cutaneous reactions may not elevate tryptase

Complete blood count (CBC):

• Eosinophilia (> 500 cells/μL): Suggests parasitic infection, drug reaction with eosinophilia (DRESS), or hypereosinophilic syndrome
• Leukocytosis with left shift: Bacterial infection

Complement levels:

• Low C4: Hereditary angioedema (HAE) or acquired C1 esterase inhibitor deficiency. Further testing: C1-INH level and function
• Normal C4: Does not exclude HAE with normal C1-INH (HAE type III with factor XII mutations)

Thyroid function and autoantibodies: 10-20% of chronic spontaneous urticaria patients have thyroid autoimmunity (Hashimoto's thyroiditis). Not routinely indicated in acute urticaria unless chronic pattern emerges. [22]

Specific IgE testing (serum or skin prick tests): Identifies IgE-mediated sensitization to specific allergens (foods, drugs, insect venoms). Typically performed in outpatient allergy clinic, not emergency setting.

Imaging

Imaging is not routinely indicated for acute urticaria. Consider in specific circumstances:

Soft tissue imaging of neck (CT or lateral soft tissue radiograph): If concern for airway-threatening angioedema and patient stable enough for imaging. Findings include:

• Epiglottic thickening
• Aryepiglottic fold edema
• Narrowing of hypopharynx or larynx

Clinical caveat: Do NOT delay definitive airway management for imaging in unstable patients with airway-threatening angioedema.

Skin Biopsy

Skin biopsy is reserved for atypical presentations or when urticarial vasculitis is suspected:

Indications:

• Individual wheals persisting > 24 hours
• Painful rather than pruritic lesions
• Residual purpura or hyperpigmentation
• Poor response to conventional antihistamine therapy

Histological findings in uncomplicated urticaria:

• Dermal edema with separation of collagen bundles
• Sparse perivascular lymphocytic infiltrate
• Dilated venules and lymphatics
• No vasculitis (intact vessel walls, no fibrinoid necrosis, no significant neutrophil infiltration)

Histological findings in urticarial vasculitis:

• Leukocytoclastic vasculitis: Neutrophil infiltration of vessel walls, fibrinoid necrosis, nuclear dust (karyorrhexis), extravasation of red blood cells [23]

---

Classification and Severity Assessment

Classification by Duration

Severity Stratification

While there is no universally accepted severity scoring system for acute urticaria, clinical severity assessment guides treatment intensity:

Mild:

• Limited distribution (less than 10% body surface area)
• Minimal pruritus not interfering with daily activities
• No angioedema
• No systemic symptoms

Moderate:

• Moderate distribution (10-50% body surface area)
• Moderate pruritus affecting sleep or daily activities
• Peripheral angioedema (hands, feet, non-airway)
• No respiratory or cardiovascular involvement

Severe:

• Extensive distribution (> 50% body surface area)
• Severe pruritus significantly impairing function
• Facial or oropharyngeal angioedema (potential airway threat)
• Refractory to initial antihistamine therapy
• Requires corticosteroid therapy

Life-threatening (Anaphylaxis):

• Respiratory compromise (stridor, wheeze, dyspnea, hypoxemia)
• Cardiovascular instability (hypotension, syncope)
• Laryngeal edema
• Requires immediate IM epinephrine

---

Management

The therapeutic approach to acute urticaria prioritizes: (1) exclusion of anaphylaxis requiring epinephrine, (2) trigger identification and avoidance, (3) pharmacological symptom control with antihistamines, and (4) appropriate patient disposition. [1,5]

General Principles

1. Rule out anaphylaxis: Any urticaria with respiratory, cardiovascular, or gastrointestinal symptoms constitutes anaphylaxis and requires immediate IM epinephrine
2. Identify and remove trigger: Discontinue suspected medications, avoid identified allergens
3. H1-antihistamines are first-line therapy: Non-sedating second-generation H1-antihistamines preferred
4. Corticosteroids for severe/refractory cases: Short course (3-5 days) for extensive or refractory urticaria
5. ACE inhibitor angioedema requires different management: Does not respond to antihistamines/corticosteroids; requires ACE inhibitor cessation and may need bradykinin antagonist therapy

Uncomplicated Acute Urticaria (No Anaphylaxis)

First-Line: Second-Generation H1-Antihistamines

Second-generation (non-sedating) H1-antihistamines are the cornerstone of acute urticaria management, demonstrating superior efficacy and safety profile compared to first-generation agents. [1,5]

Evidence base: Multiple randomized controlled trials demonstrate efficacy of second-generation H1-antihistamines in acute urticaria, with symptom relief in 60-80% of patients within 24-48 hours. [5,25]

Dosing considerations:

• Standard licensed doses are effective for most patients
• Up-dosing: For refractory cases, international guidelines support increasing dose up to 4-fold (e.g., cetirizine 40 mg daily, though evidence is stronger for chronic urticaria) [1]
• Food interactions: Fexofenadine absorption decreased by 50% with fruit juices; advise taking with water

Comparative efficacy: Head-to-head trials show minimal efficacy differences between second-generation agents; choice based on patient factors (cost, formulation preference, side effect profile)

First-Generation H1-Antihistamines (Sedating)

First-generation antihistamines cross the blood-brain barrier causing significant sedation and anticholinergic effects. Reserved for specific scenarios:

Disadvantages:

• Sedation, impaired cognition, reduced psychomotor performance (contraindicated when driving/operating machinery)
• Anticholinergic effects: Dry mouth, urinary retention, constipation, confusion (particularly in elderly)
• Drug interactions via CYP2D6 inhibition
• Not recommended for long-term use [1,5]

Clinical pearl: Despite sedation concerns, diphenhydramine 25-50 mg IV provides rapid symptom relief in emergency department and may be preferred in acute setting when patient will be observed or driven home.

Second-Line: Add H2-Receptor Antagonists

H2-antihistamines block histamine H2 receptors on vascular endothelium and may provide additive benefit when combined with H1-antihistamines, though evidence is conflicting. [26]

Evidence: Meta-analysis suggests combination H1+H2 blockade provides marginal benefit over H1-antihistamines alone, with number needed to treat (NNT) of 8-10 for symptom improvement. [26] Routine use not strongly supported by current evidence; consider for refractory cases.

Third-Line: Short-Course Oral Corticosteroids

Systemic corticosteroids are indicated for severe or refractory acute urticaria not responding to antihistamines within 24-48 hours, or extensive urticaria with significant impact on quality of life. [27]

Evidence: While widely used in clinical practice, high-quality evidence supporting corticosteroid efficacy in acute urticaria is limited. A 2024 systematic review found insufficient RCT evidence to definitively recommend corticosteroids, but clinical experience and observational data support use in severe cases. [27] Corticosteroids may reduce urticaria duration and prevent recurrence in the short term.

Dosing strategy:

• Short course (3-5 days) sufficient for most acute episodes
• Tapering not necessary for courses less than 7 days
• Longer courses (7-14 days) may be considered for persistent symptoms, with taper to prevent rebound

Adverse effects: Short-course corticosteroids generally well-tolerated. Potential effects include hyperglycemia (monitor in diabetics), mood changes, insomnia, gastrointestinal upset, and fluid retention.

Caution: Avoid routine corticosteroid use for mild uncomplicated urticaria; reserve for severe or refractory cases.

Adjunctive Therapies

Leukotriene receptor antagonists (LTRAs):

• Montelukast 10 mg PO once daily: Blocks cysteinyl leukotriene receptors
• Evidence: Limited data for acute urticaria; some benefit reported for chronic urticaria, particularly NSAID-exacerbated urticaria and aspirin-sensitive patients [28]
• May be considered as add-on therapy for refractory cases

Topical therapies:

• Calamine lotion or menthol-containing creams: Provide temporary symptomatic relief from pruritus through cooling effect
• Topical corticosteroids: NOT effective for urticaria (lesions originate in dermis, not epidermis); do not use

Avoid triggers:

• Discontinue suspected causative medications (NSAIDs, antibiotics, ACE inhibitors)
• Avoid known food allergens
• Minimize physical triggers (temperature extremes, pressure, exercise if triggering)
• Avoid alcohol and hot environments (vasodilators that may worsen symptoms)

Angioedema Without Anaphylaxis

Histamine-Mediated Angioedema (Accompanying Urticaria)

Managed identically to urticaria:

• H1-antihistamines (non-sedating second-generation preferred)
• ± H2-antihistamines
• ± Corticosteroids for severe cases
• Close airway monitoring if oropharyngeal involvement

Disposition considerations:

• Peripheral angioedema (hands, feet, genitals): May discharge with antihistamines if improving and no airway involvement
• Facial/lip angioedema: Observe for progression; discharge if stable and clearly improving
• Tongue or oropharyngeal angioedema: Admission for continuous monitoring even if improving; airway compromise can develop over hours

ACE Inhibitor-Induced Angioedema

ACE inhibitor angioedema is a bradykinin-mediated process mechanistically distinct from histamine-mediated urticaria. Occurs in 0.1-0.7% of ACE inhibitor users, with 3-4.5 fold higher incidence in Black patients. [4,20]

Key management principles:

1. Immediately discontinue ACE inhibitor: Permanent contraindication; document allergy in medical record. Angioedema can recur or worsen with continued use.

2. Antihistamines and corticosteroids are NOT effective: Do not waste time with therapies that do not address bradykinin-mediated mechanism. [4]

3. Airway management is paramount:

   • Continuous monitoring in resuscitation area or ICU
   • Early anesthesia/ENT consultation if tongue or oropharyngeal involvement
   • Low threshold for definitive airway (intubation) before complete obstruction develops
   • Fiberoptic intubation may be required; surgical airway (cricothyrotomy) may be necessary if intubation fails

4. Specific bradykinin antagonist therapies:

Evidence for icatibant: The FAST-3 randomized controlled trial compared icatibant to placebo in ACE inhibitor-induced angioedema. Icatibant demonstrated faster time to complete resolution (median 8 hours vs 27 hours, p=0.02) and lower intubation rates (trend toward significance). [4] However, icatibant is expensive and not universally available.

Practical approach when specific agents unavailable:

• Discontinue ACE inhibitor
• Aggressive airway management (do not delay intubation)
• Fresh frozen plasma (2-4 units IV) may be tried while preparing for intubation
• Antihistamines/corticosteroids may be administered empirically (low risk, though unlikely benefit)

5. Alternative antihypertensives: After resolution, switch to alternative agent. Angiotensin receptor blockers (ARBs) have lower risk of angioedema (~0.1-0.2% incidence) but cross-reactivity reported in 2-17% of cases. [20] Consider alternative drug class (calcium channel blocker, thiazide diuretic) if possible.

Hereditary Angioedema (HAE)

While HAE typically presents with recurrent episodes from childhood/adolescence, first presentation in adulthood occasionally occurs. Characterized by recurrent angioedema WITHOUT urticaria. [21]

Diagnostic clues:

• Recurrent episodes of angioedema (face, extremities, genitals, GI tract)
• No urticaria
• Family history (autosomal dominant inheritance)
• Precipitated by trauma, stress, infections, estrogen exposure
• Abdominal attacks (intestinal wall edema causing pain, nausea, vomiting)

Laboratory diagnosis:

• Low C4 level (screening test; low in > 95% of HAE type I and II during and between attacks)
• C1 esterase inhibitor (C1-INH): Quantitative level (low in type I; normal/high in type II) and functional assay (low function in both types I and II)
• HAE with normal C1-INH (type III): Normal C4 and C1-INH; factor XII mutations in some cases

Acute management: Same bradykinin-targeted therapies as ACE inhibitor angioedema, but with stronger evidence base:

• C1-INH concentrate (pdC1-INH or rhC1-INH): First-line; FDA-approved for HAE acute attacks [29]
• Icatibant 30 mg SC: FDA-approved for HAE acute attacks
• Ecallantide (kallikrein inhibitor) 30 mg SC: FDA-approved for HAE (not available in all countries)

Long-term prophylaxis (Allergy/Immunology referral): Androgens (danazol, stanozolol), C1-INH concentrate, lanadelumab (anti-kallikrein monoclonal antibody)

Anaphylaxis (Urticaria with Systemic Involvement)

Anaphylaxis is a medical emergency requiring immediate intervention. Any patient presenting with urticaria PLUS respiratory, cardiovascular, or gastrointestinal symptoms should be treated for anaphylaxis. [24]

Immediate Management (Within Minutes)

1. IM Epinephrine (First-line, life-saving intervention):

Rationale for IM epinephrine:

• α1-adrenergic effects: Vasoconstriction, reverses hypotension, reduces angioedema
• β1-adrenergic effects: Positive inotropy and chronotropy, improves cardiac output
• β2-adrenergic effects: Bronchodilation, reduces bronchospasm, stabilizes mast cells

Route considerations: IM injection into thigh achieves peak plasma levels within 5-10 minutes and is significantly more effective than subcutaneous injection (which is NOT recommended due to variable absorption). IV epinephrine (infusion) reserved for refractory anaphylaxis with cardiovascular collapse, requiring intensive monitoring. [24]

Common errors:

• ❌ Delaying epinephrine while administering antihistamines/corticosteroids first
• ❌ Using subcutaneous route (less effective)
• ❌ Underdosing (less than 0.3 mg in adults)
• ❌ Failing to repeat doses when symptoms persist

2. Patient Positioning:

• Supine position with legs elevated (unless vomiting or respiratory distress)
• Avoid upright positioning (can precipitate cardiovascular collapse)
• If respiratory distress, allow position of comfort (often semi-recumbent)

3. Remove Trigger (if possible):

• Stop medication infusion (e.g., antibiotic, blood transfusion)
• Remove insect stinger if present

4. Airway Assessment and Management:

• Assess for stridor, voice changes, difficulty swallowing
• Administer high-flow oxygen (target SpO2 > 94%)
• Early anesthesia consultation if airway-threatening angioedema
• Prepare for emergency intubation or cricothyrotomy if airway compromise

5. IV Access and Fluid Resuscitation:

• Establish large-bore IV access (×2 if possible)
• Crystalloid fluid bolus: 1-2 liters (20 mL/kg in children) rapidly for hypotension
• May require several liters in distributive shock
• Vasopressors (norepinephrine, epinephrine infusion) if refractory hypotension despite fluids and repeated IM epinephrine

Adjunctive Pharmacological Therapies (Secondary to Epinephrine)

H1-antihistamines:

• Diphenhydramine 25-50 mg IV
• Provides symptom relief but does NOT reverse life-threatening manifestations
• NOT a substitute for epinephrine

H2-antihistamines:

• Famotidine 20 mg IV
• Marginal additional benefit; commonly co-administered with H1-antihistamines

Corticosteroids:

• Methylprednisolone 125 mg IV or hydrocortisone 200 mg IV
• May reduce risk of biphasic reactions (controversial; evidence is weak)
• Delayed onset of action (4-6 hours); does NOT treat acute symptoms
• Typically administered in ED setting despite limited evidence [24]

Bronchodilators (if bronchospasm):

• Albuterol (salbutamol) nebulized 2.5-5 mg
• Adjunct to epinephrine for persistent bronchospasm; NOT a substitute

Glucagon (if patient on beta-blockers):

• Beta-blockers may blunt response to epinephrine
• Glucagon 1-2 mg IV bolus, followed by infusion 5-15 μg/min
• Works via non-adrenergic mechanism to increase cardiac contractility and bronchodilation

Refractory Anaphylaxis

Defined as poor response to ≥2 doses of IM epinephrine and aggressive fluid resuscitation. Management requires ICU-level care:

• IV epinephrine infusion: 0.05-0.1 μg/kg/min, titrate to effect (requires continuous cardiac monitoring)
• Vasopressors: Norepinephrine, vasopressin for refractory hypotension
• Mechanical ventilation: If respiratory failure
• Extracorporeal membrane oxygenation (ECMO): Case reports in near-fatal anaphylaxis refractory to all therapies

Biphasic Anaphylaxis

Biphasic reactions occur in 3-20% of anaphylaxis cases, with symptom recurrence after initial resolution, typically within 8-12 hours (range 1-72 hours). [24] Risk factors include severe initial reaction, delayed epinephrine administration, and prolonged allergen exposure.

Observation period: All patients with anaphylaxis should be observed for minimum 4-6 hours (some guidelines recommend 8-24 hours for severe reactions or delayed epinephrine). [24]

Discharge criteria after anaphylaxis:

• Complete resolution of symptoms for ≥4-6 hours
• Normal vital signs
• Adequate response to IM epinephrine (did not require multiple doses or IV epinephrine)
• Trigger identified and avoidable
• Epinephrine auto-injector prescribed and patient educated on use
• Allergy referral arranged

Special Populations

Pregnancy

Acute urticaria and anaphylaxis can occur during pregnancy, requiring careful therapeutic decision-making balancing maternal benefit and fetal safety. [30]

Antihistamines in pregnancy:

• Cetirizine and loratadine: Category B; preferred agents based on safety data
• Fexofenadine and desloratadine: Category C; limited human data
• Diphenhydramine: Category B, but avoid in first trimester due to theoretical risk
• Chlorpheniramine: Category B; alternative first-generation agent if needed

Corticosteroids in pregnancy:

• Prednisone/prednisolone: Minimal placental transfer (inactivated by placental 11β-hydroxysteroid dehydrogenase); acceptable for short courses
• Weigh benefits vs. risks (first trimester: theoretical cleft palate risk; third trimester: potential fetal growth restriction with prolonged use)

Epinephrine in pregnancy:

• Category C, but absolutely indicated for anaphylaxis
• Maternal hypoxemia and hypotension far more dangerous to fetus than epinephrine
• No hesitation to administer IM epinephrine for anaphylaxis in pregnancy [30]

Fetal monitoring: After anaphylaxis or severe urticaria in pregnancy > 24 weeks, fetal monitoring (non-stress test, ultrasound) recommended to assess fetal well-being.

Elderly Patients

Antihistamine selection:

• Avoid first-generation antihistamines (diphenhydramine, hydroxyzine): Increased risk of falls, confusion, urinary retention, cognitive impairment
• Prefer second-generation agents: Cetirizine, loratadine, fexofenadine
• Dose adjustment: Consider reduced doses in renal impairment (e.g., cetirizine 5 mg daily if CrCl less than 30 mL/min)

Polypharmacy considerations:

• Review medication list for ACE inhibitors (angioedema risk)
• Drug-drug interactions with antihistamines (particularly first-generation agents)

Anaphylaxis management: No dose adjustment for epinephrine; administer full 0.3-0.5 mg IM dose. Elderly patients may have increased cardiovascular complications; close monitoring required.

Pediatric Considerations

Acute urticaria is common in children, often triggered by viral infections. [12]

Antihistamine dosing (weight-based):

• Cetirizine:
  • 6 months-2 years: 2.5 mg once daily
  • 2-6 years: 2.5-5 mg once daily
  • ≥6 years: 5-10 mg once daily
• Loratadine:
  • 2-5 years: 5 mg once daily
  • ≥6 years: 10 mg once daily

Anaphylaxis epinephrine dosing:

• 0.01 mg/kg IM (maximum 0.5 mg)
• Weight-based auto-injector devices: less than 25 kg = 0.15 mg; ≥25 kg = 0.3 mg

Common triggers in children: Viral infections (most common), food allergies (milk, eggs, peanuts), antibiotics (amoxicillin)

---

Prognosis and Natural History

Acute Urticaria

The prognosis for acute urticaria is excellent, with the majority of cases resolving spontaneously within days to 2 weeks. [9,10]

Prognostic factors for prolonged course or chronicity:

• Older age (adults > 40 years)
• Severity of initial presentation (extensive urticaria)
• Angioedema accompanying wheals
• Elevated inflammatory markers (ESR/CRP) suggesting urticarial vasculitis
• Positive autologous serum skin test (suggests autoimmune component) [22]

Recurrence Risk

Recurrence of acute urticaria depends on trigger:

• Identifiable allergen (food, drug, insect): Recurrence prevented by avoidance; less than 5% recurrence if trigger successfully avoided
• Viral infection-triggered: Low recurrence risk; each episode associated with new infection
• Idiopathic acute urticaria: ~15-20% may have recurrent episodes or progress to chronic pattern [10]

Chronic Urticaria Outcomes

Among patients who progress to chronic spontaneous urticaria (CSU):

• 30-50% achieve remission within 1 year
• Additional 20% remit each subsequent year
• Median duration: 3-5 years
• 10-20% have persistent symptoms > 20 years [10]

Anaphylaxis Recurrence and Mortality

For patients who experience anaphylaxis:

• Recurrence risk: 30-60% if trigger not identified and avoided
• Mortality: Anaphylaxis carries case fatality rate of ~0.1-0.3%, with higher risk in those with delayed epinephrine, underlying asthma, or cardiovascular disease [24]
• Biphasic reactions: Occur in 3-20% of cases, necessitating observation period

---

Prevention and Trigger Avoidance

Primary Prevention

For individuals with documented IgE-mediated allergies (food, drug, insect venom):

Allergen avoidance:

• Read ingredient labels carefully for food allergens
• Carry epinephrine auto-injector at all times if history of anaphylaxis
• Medical alert bracelet identifying specific allergens
• Educate family, school, workplace about allergen and emergency management

Venom immunotherapy (VIT):

• Indicated for patients with systemic reactions to Hymenoptera stings
• Reduces risk of subsequent systemic reactions from > 60% to less than 5% [31]
• Administered over 3-5 years; 80-90% efficacy

Medication allergies:

• Document all drug allergies in medical record
• Educate patient to inform all healthcare providers
• Consider drug desensitization in selected cases where medication is essential and no alternatives exist (e.g., penicillin desensitization for syphilis in pregnancy)

Secondary Prevention (Preventing Recurrence)

Trigger diary: Patients with recurrent urticaria should maintain detailed diary documenting:

• Food intake
• Medications
• Activities and exposures
• Symptom timing and severity
• Potential patterns or triggers

Avoidance strategies for physical urticarias:

• Cold urticaria: Avoid cold water swimming, gradual cooling when necessary
• Cholinergic urticaria: Avoid hot showers, vigorous exercise (or premedicate with antihistamines)
• Solar urticaria: UV-protective clothing, broad-spectrum sunscreen
• Pressure urticaria: Avoid tight clothing, prolonged pressure

NSAID avoidance: Patients with NSAID-induced urticaria should avoid all non-selective COX inhibitors. Selective COX-2 inhibitors (celecoxib) may be tolerated in some cases, but require supervised challenge. Acetaminophen (paracetamol) is generally safe alternative.

---

Patient Education and Discharge Instructions

Explanation of Condition

Lay language explanation: "You have hives, also called urticaria, which is an allergic-type reaction causing raised, itchy bumps on your skin. These are caused by release of histamine from cells in your skin. Most cases resolve on their own within a few days with antihistamine medication."

When angioedema present: "You also have angioedema, which is deeper swelling in the skin, most noticeable on your lips/face/hands. This is related to the hives and usually resolves with the same treatment."

Home Management

Antihistamine therapy:

• Take prescribed antihistamine (cetirizine 10 mg or loratadine 10 mg) once daily, even if symptoms improve
• Continue for at least 3-5 days after symptoms resolve to prevent recurrence
• May cause mild drowsiness; avoid driving if affected (especially with first-generation antihistamines)

Trigger avoidance:

• Stop any suspected medications (particularly NSAIDs, new antibiotics) and contact prescribing physician for alternatives
• Avoid identified food allergens
• Avoid alcohol, hot environments, and vigorous exercise (may worsen symptoms)

Symptomatic measures:

• Cool compresses to affected areas for itch relief
• Wear loose-fitting clothing to avoid pressure on skin
• Keep fingernails short to prevent skin damage from scratching
• Lukewarm (not hot) showers

When to Return to Emergency Department or Call 911

Immediate emergency (call 911):

• Difficulty breathing, wheezing, or shortness of breath
• Throat tightness or difficulty swallowing
• Swelling of tongue or throat
• Feeling faint, dizzy, or lightheaded
• Voice changes or hoarseness
• Severe abdominal pain with vomiting

Return to ED (non-emergency):

• Worsening or spreading rash despite antihistamines
• New swelling of lips, face, or eyes
• Symptoms not improving after 48 hours of treatment
• Individual hives lasting > 24 hours in same location
• Development of painful lesions or bruising

Epinephrine Auto-Injector Education (If Prescribed After Anaphylaxis)

Indications for prescribing epinephrine:

• History of anaphylaxis
• Urticaria/angioedema associated with respiratory or cardiovascular symptoms
• Food allergy with systemic reaction
• Insect venom allergy with systemic reaction

Patient education points:

• Carry auto-injector at all times (do not leave in car due to temperature extremes)
• When to use: Any signs of anaphylaxis (breathing difficulty, throat swelling, dizziness, widespread hives with systemic symptoms)
• How to use: Remove safety cap, place orange tip against mid-outer thigh, press firmly until click heard, hold for 3 seconds
• After injection: Call 911 immediately; lie down with legs elevated; may repeat dose after 5-15 minutes if no improvement
• Two auto-injectors recommended: First dose may not be sufficient; ~10-20% require second dose

Auto-injector devices:

• EpiPen®, Auvi-Q®, generic epinephrine auto-injectors
• Adult dose: 0.3 mg
• Pediatric dose (less than 25 kg): 0.15 mg
• Demonstrate technique; consider trainer device for practice

Allergy Referral

Indications for outpatient allergy/immunology referral:

• Anaphylaxis (for trigger identification, testing, immunotherapy consideration)
• Recurrent acute urticaria episodes
• Progression to chronic urticaria (symptoms > 6 weeks)
• Suspected food allergy requiring confirmation and management plan
• Insect venom allergy (for venom immunotherapy)
• Angioedema without urticaria (evaluate for hereditary angioedema)

---

Complications

Complications of acute urticaria are uncommon but include:

Progression to Anaphylaxis

Most serious complication; occurs in ~1-3% of acute urticaria presentations. [24] Risk factors include:

• Previous anaphylaxis
• Known severe allergies (food, drug, insect venom)
• Asthma (increases severity and mortality risk)
• Rapidly progressive urticaria with facial angioedema

Airway Compromise from Angioedema

Laryngeal edema can occur with angioedema involving tongue, soft palate, or posterior pharynx. Mortality from asphyxiation reported, particularly with ACE inhibitor angioedema or hereditary angioedema. [4,21]

Chronic Urticaria Development

10-20% of acute urticaria cases progress to chronic spontaneous urticaria (symptoms > 6 weeks), which significantly impacts quality of life and may require prolonged treatment. [10]

Psychological Impact

Severe, recurrent urticaria can cause:

• Anxiety about recurrence
• Depression (particularly in chronic urticaria)
• Sleep disturbance from nocturnal pruritus
• Social embarrassment and avoidance behaviors
• Reduced quality of life scores comparable to coronary artery disease patients [32]

Medication Adverse Effects

• Antihistamine sedation: Particularly first-generation agents; impairs driving and occupational performance
• Corticosteroid adverse effects: Short courses generally safe; prolonged use (> 2 weeks) risks hyperglycemia, weight gain, osteoporosis, immunosuppression

---

Key Guidelines and Consensus Statements

International Guidelines

European Academy of Allergy and Clinical Immunology (EAACI)/Global Allergy and Asthma European Network (GA²LEN)/European Dermatology Forum (EDF)/World Allergy Organization (WAO) Guideline 2022 [1]:

• Second-generation H1-antihistamines are first-line treatment
• Up-dosing antihistamines (up to 4-fold) for refractory cases
• Short-course corticosteroids for severe acute urticaria
• Avoid routine investigations in uncomplicated cases

British Society for Allergy and Clinical Immunology (BSACI) Guideline 2021:

• Non-sedating antihistamines preferred over sedating agents
• Limited role for H2-antihistamines (weak evidence)
• Omalizumab for refractory chronic urticaria (not acute)

American Academy of Allergy, Asthma, and Immunology (AAAAI) 2014 Practice Parameter Update [5]:

• Clinical diagnosis; laboratory testing not routinely needed
• H1-antihistamines are mainstay
• Corticosteroids for refractory cases (short course)

World Allergy Organization (WAO) Anaphylaxis Guidance 2020 [24]:

• IM epinephrine is first-line treatment for anaphylaxis
• Antihistamines and corticosteroids are adjuncts only
• Observation period of 4-6 hours minimum after anaphylaxis

---

Exam-Focused Content

Viva Point: ### Opening Statement for Viva

"Acute urticaria is a common dermatological condition characterized by transient, pruritic, erythematous wheals lasting less than 24 hours in any single location, with overall episode duration of less than 6 weeks. It results from mast cell degranulation and histamine release in the dermis, and affects approximately 15-25% of the population at some point in their lifetime. The key clinical tasks are distinguishing uncomplicated urticaria from anaphylaxis, identifying potential triggers when possible, and providing appropriate antihistamine-based management."

Key Facts for Examinations

Pathophysiology: Mast cell activation → release of preformed mediators (histamine, tryptase) and newly synthesized mediators (prostaglandin D2, leukotrienes) → increased vascular permeability and vasodilation → dermal edema (wheal) and erythema (flare) [2,18]

Diagnostic criteria: (1) Transient wheals, (2) Individual lesions less than 24 hours duration, (3) Pruritic, (4) Blanching erythema, (5) No residual skin changes

Acute vs. Chronic: Acute less than 6 weeks; Chronic ≥6 weeks. Acute more common (~60-70% of urticaria cases), usually identifiable trigger, excellent prognosis. [9]

Angioedema distinction: Deeper tissue involvement (dermis and subcutaneous), lasts 24-72 hours, less pruritic, affects loose connective tissue sites (lips, periorbital, tongue, genitals). Occurs with urticaria in 40-50% of cases. [2]

First-line treatment: Non-sedating second-generation H1-antihistamines (cetirizine 10 mg, loratadine 10 mg, fexofenadine 180 mg) daily. [1,5]

Corticosteroids: Reserved for severe/refractory cases; prednisone 40-60 mg daily for 3-5 days. [27]

ACE inhibitor angioedema: Bradykinin-mediated (NOT histamine); does NOT respond to antihistamines/corticosteroids; requires ACE inhibitor cessation and may need icatibant or C1-INH concentrate. [4,20]

Anaphylaxis management: IM epinephrine 0.3-0.5 mg (1:1,000 concentration) into mid-anterolateral thigh is first-line; antihistamines and corticosteroids are adjuncts only. [24]

Common Exam Questions

Q1: "What are the common causes of acute urticaria?"

A: "The causes of acute urticaria can be categorized as follows:

Infections (30-50% of identifiable cases): Viral URTIs are most common, particularly in children. Bacterial infections such as streptococcal pharyngitis also implicated.

Medications (20-30%): NSAIDs through direct mast cell activation, antibiotics (penicillins, cephalosporins, sulfonamides) via IgE-mediated mechanisms, ACE inhibitors causing bradykinin-mediated angioedema, and opioids through direct histamine release.

Foods (10-20%): Common allergens include shellfish, peanuts, tree nuts, eggs, milk, fish. IgE-mediated reactions typically occur within minutes to 2 hours of ingestion.

Insect stings: Hymenoptera venom (bees, wasps) causing IgE-mediated reactions.

Physical stimuli: Dermographism, cold urticaria, cholinergic urticaria (heat/exercise), pressure urticaria.

Idiopathic (40-60%): No identifiable trigger despite thorough investigation; most common category.

It's important to note that in approximately 40-60% of acute urticaria cases, a specific trigger cannot be identified." [1,15]

Q2: "How do you differentiate urticaria from urticarial vasculitis?"

A: "The key distinguishing features are:

The duration of individual lesions is the single most important clinical discriminator. Skin biopsy showing leukocytoclastic vasculitis confirms urticarial vasculitis diagnosis." [23]

Q3: "Describe your management approach to acute urticaria in the emergency department."

A: "My approach would be systematic:

1. Exclude anaphylaxis: Assess for systemic involvement. Any urticaria with respiratory symptoms (wheeze, stridor, dyspnea), cardiovascular instability (hypotension, syncope), or gastrointestinal symptoms (cramping, vomiting in context) constitutes anaphylaxis requiring immediate IM epinephrine 0.3-0.5 mg.

2. Assess airway if angioedema: Examine oropharynx for tongue, uvular, or posterior pharyngeal swelling. If present, continuous monitoring and low threshold for definitive airway management.

3. Identify trigger: Detailed history for medication exposure (especially NSAIDs, antibiotics, ACE inhibitors within past 2-4 weeks), food allergens, insect stings, recent infections, or physical stimuli.

4. First-line pharmacotherapy: Non-sedating H1-antihistamine such as cetirizine 10 mg or loratadine 10 mg orally. For acute symptom relief in ED, diphenhydramine 25-50 mg IV may be used despite sedation.

5. Adjunctive therapy: For moderate-to-severe urticaria, add H2-antihistamine (famotidine 20 mg) and short-course corticosteroid (prednisone 40-60 mg daily for 3-5 days).

6. Special consideration for ACE inhibitor angioedema: If angioedema without urticaria in patient on ACE inhibitor, discontinue medication immediately. Antihistamines and corticosteroids will NOT work. Consider icatibant, C1-INH concentrate, or FFP if available and airway-threatening.

7. Disposition: Uncomplicated urticaria improving with antihistamines may be discharged with prescription and trigger avoidance instructions. Admit for angioedema with airway involvement, anaphylaxis (observe minimum 4-6 hours), or refractory symptoms." [1,5,24]

Q4: "What is the mechanism of ACE inhibitor-induced angioedema and how does management differ?"

A: "ACE inhibitor-induced angioedema is mechanistically distinct from histamine-mediated urticaria:

Mechanism: Angiotensin-converting enzyme (ACE) normally degrades bradykinin. ACE inhibition leads to bradykinin accumulation. Bradykinin binds to B2 receptors on endothelial cells, causing increased vascular permeability and angioedema in deep dermal and submucosal tissues. This is NOT a histamine-mediated process. [4,20]

Epidemiology: Occurs in 0.1-0.7% of ACE inhibitor users, with 3-4.5 fold higher incidence in Black patients. Can occur within days or after years of ACE inhibitor use.

Clinical features: Angioedema WITHOUT urticaria (wheals), affecting lips, tongue, oropharynx. Potentially life-threatening due to laryngeal involvement.

Management differences:

1. Immediately discontinue ACE inhibitor – permanent contraindication

2. Antihistamines and corticosteroids are NOT effective – do not waste time with these therapies

3. Airway management is paramount – low threshold for intubation before complete obstruction

4. Specific bradykinin antagonists (if available):

   • Icatibant 30 mg SC (bradykinin B2 receptor antagonist): RCT showed faster resolution vs. placebo [4]
   • C1 esterase inhibitor concentrate: Inhibits kallikrein-bradykinin pathway
   • Fresh frozen plasma: Contains ACE to degrade bradykinin (use if specific agents unavailable)

5. Alternative antihypertensives: Switch to non-ACE inhibitor/ARB agent (calcium channel blocker, thiazide); ARBs have lower risk but 2-17% cross-reactivity reported. [20]

The key is recognizing that this is a bradykinin-mediated process requiring different therapeutic targets than histamine-mediated urticaria."

Common Mistakes in Examinations

❌ Failing to distinguish uncomplicated urticaria from anaphylaxis: Urticaria alone does NOT require epinephrine; anaphylaxis (urticaria + systemic involvement) does. Candidates often either over-treat uncomplicated urticaria with epinephrine or under-treat anaphylaxis by omitting epinephrine.

❌ Stating that individual wheals last > 24 hours: This is pathognomonic of urticarial vasculitis, NOT urticaria. Individual urticarial wheals resolve within less than 24 hours (usually minutes to hours).

❌ Treating ACE inhibitor angioedema with antihistamines/corticosteroids: Bradykinin-mediated angioedema does NOT respond to these agents. Failure to discontinue ACE inhibitor and provide appropriate bradykinin-targeted therapy.

❌ Using subcutaneous epinephrine for anaphylaxis: IM route into anterolateral thigh is required for rapid, reliable absorption. SC route is obsolete.

❌ Ordering extensive laboratory workup for uncomplicated acute urticaria: Urticaria is a clinical diagnosis; routine blood tests are not indicated unless atypical features or chronicity.

❌ Confusing angioedema with urticaria: Candidates often use terms interchangeably. Angioedema is deeper tissue swelling (dermis/subcutaneous), lasts longer (24-72h), less pruritic, affects specific anatomical sites (lips, periorbital, tongue).

---

References

1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766. doi:10.1111/all.15090

2. Kaplan AP. Urticaria and angioedema. In: Adkinson NF, et al., eds. Middleton's Allergy: Principles and Practice. 8th ed. Elsevier; 2014:575-589.

3. Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol. 2010;35(8):869-873. doi:10.1111/j.1365-2230.2010.03840.x

4. Bas M, Greve J, Stelter K, et al. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med. 2015;372(5):418-425. doi:10.1056/NEJMoa1312524

5. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-1277. doi:10.1016/j.jaci.2014.02.036

6. Dressler C, Werner RN, Eisert L, et al. Chronic inducible urticaria: a systematic review of treatment options. J Allergy Clin Immunol. 2018;141(5):1726-1734. doi:10.1016/j.jaci.2017.11.043

7. Sánchez-Borges M, Asero R, Ansotegui IJ, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J. 2012;5(11):125-147. doi:10.1097/WOX.0b013e3182758d6c

8. Gaig P, Olona M, Muñoz Lejarazu D, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol. 2004;14(3):214-220.

9. Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol. 2001;45(3):387-391. doi:10.1067/mjd.2001.116217

10. Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy. 2004;59(8):869-873. doi:10.1111/j.1398-9995.2004.00473.x

11. Greaves MW. Chronic urticaria in perspective. Clin Exp Dermatol. 1995;20(2):103-108. doi:10.1111/j.1365-2230.1995.tb01275.x

12. Kulthanan K, Chiawsirikajorn Y, Jiamton S. Acute urticaria: etiologies, clinical course and quality of life. Asian Pac J Allergy Immunol. 2008;26(1):1-9.

13. Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68(10):1219-1232. doi:10.1111/all.12260

14. Ye YM, Park JW, Kim SH, et al. Clinical evaluation of the role of serum histamine levels in chronic urticaria and anaphylaxis. Allergy Asthma Immunol Res. 2012;4(6):357-361. doi:10.4168/aair.2012.4.6.357

15. Champion RH, Roberts SO, Carpenter RG, Roger JH. Urticaria and angio-oedema. A review of 554 patients. Br J Dermatol. 1969;81(8):588-597. doi:10.1111/j.1365-2133.1969.tb16041.x

16. Sicherer SH, Sampson HA. Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol. 2018;141(1):41-58. doi:10.1016/j.jaci.2017.11.003

17. Rajan JP, Simon RA, Bosso JV. Prevalence of sensitivity to food and drug additives in patients with chronic idiopathic urticaria. J Allergy Clin Immunol Pract. 2014;2(2):168-171. doi:10.1016/j.jaip.2013.12.003

18. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704. doi:10.1038/nm.2755

19. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med. 2007;357(18):1841-1854. doi:10.1056/NEJMra071371

20. Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165(14):1637-1642. doi:10.1001/archinte.165.14.1637

21. Zuraw BL, Christiansen SC. Pathophysiology of hereditary angioedema. Am J Rhinol Allergy. 2011;25(6):373-378. doi:10.2500/ajra.2011.25.3661

22. Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. J Allergy Clin Immunol. 2017;139(6):1772-1781. doi:10.1016/j.jaci.2016.08.050

23. Davis MD, Brewer JD. Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome. Immunol Allergy Clin North Am. 2004;24(2):183-213. doi:10.1016/j.iac.2004.01.008

24. Cardona V, Ansotegui IJ, Ebisawa M, et al. World Allergy Organization Anaphylaxis Guidance 2020. World Allergy Organ J. 2020;13(10):100472. doi:10.1016/j.waojou.2020.100472

25. Sharma M, Bennett C, Cohen SN, Carter B. H1-antihistamines for chronic spontaneous urticaria: an abridged Cochrane Systematic Review. J Am Acad Dermatol. 2015;73(4):710-716. doi:10.1016/j.jaad.2015.06.048

26. Pollack CV Jr, Romano TJ. Outpatient management of acute urticaria: the role of prednisone. Ann Emerg Med. 1995;26(5):547-551. doi:10.1016/s0196-0644(95)70002-8

27. Kanani A, Betschel SD, Warrington R. Urticaria and angioedema. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):59. doi:10.1186/s13223-018-0288-z

28. Di Lorenzo G, Pacor ML, Mansueto P, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol. 2004;114(3):619-625. doi:10.1016/j.jaci.2004.06.018

29. Craig T, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124(4):801-808. doi:10.1016/j.jaci.2009.07.017

30. Simons FE, Schatz M. Anaphylaxis during pregnancy. J Allergy Clin Immunol. 2012;130(3):597-606. doi:10.1016/j.jaci.2012.06.035

31. Golden DB, Moffitt J, Nicklas RA, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol. 2011;127(4):852-854. doi:10.1016/j.jaci.2011.01.025

32. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197-201. doi:10.1046/j.1365-2133.1997.d01-1168.x